Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMV367 in Healthy Adults Experimentally Infected With Plasmodium Falciparum
NCT05979207Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MMV367 in malaria (6 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Maximum Effect, Half Maximal Effective Concentration and 3 more. Started Aug 2023; status: completed.
02
Drugs
MMV367
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05979207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979207.